Department of Hepatobiliary Surgery (1), Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Ann Surg Oncol. 2024 Oct;31(10):6564-6565. doi: 10.1245/s10434-024-15772-1. Epub 2024 Aug 8.
Intrahepatic cholangiocarcinoma (ICCA) with hepatic hilus involvement is a more aggressive type of cholangiocarcinoma with worse outcomes. Surgical resection with negative margins is the only effective treatment for ICCA. Neoadjuvant therapy is considered to improve the possibility of surgery for patients; however, laparoscopic radical resection after neoadjuvant therapy for ICCA with hepatic hilus involvement remains at the exploratory stage due to technical challenges. METHODS: A 19-year-old man presented with an ICCA on the left side of the liver invading the blood vessels and bile ducts in the hepatic hilum. Five courses of neoadjuvant therapy were administered after a multidisciplinary team determined that the tumor was extremely difficult and risky to operate on. A laparoscopic left hepatectomy plus caudal lobectomy was performed to complete the resection of the negative margins. Three-dimensional visualization enabled precise preoperative planning and intraoperative guidance, including visualization of the tumor location, simulation of bile duct and vessel dissection steps, as well as determining the extent of liver resection. Vascular skeletonization, lymphadenectomy and biliary reconstruction were performed during operation.
The operation time was 415 min with a blood loss of 100 mL. Postoperative pathohistology confirmed cholangiocarcinoma with low to intermediate differentiation. The resection margin was negative (R0) and lymph node pathology was tumor-negative (0/10). The patient was discharged on postoperative day 10 without complications.
Laparoscopic radical resection after neoadjuvant therapy for ICCA with hepatic hilus involvement is safe and feasible in a large-throughput hepatic surgery center.
肝门部胆管癌(ICCAs)合并肝门部受累是一种侵袭性更强、预后更差的胆管癌类型。肝门部胆管癌的唯一有效治疗方法是阴性切缘的手术切除。新辅助治疗被认为可以提高手术的可能性,但由于技术挑战,腹腔镜根治性切除合并肝门部受累的 ICCA 仍处于探索阶段。
一名 19 岁男性,因左肝胆管癌侵犯肝门部血管和胆管而就诊。多学科团队评估后认为肿瘤手术难度和风险极高,患者接受了 5 个疗程的新辅助治疗。行腹腔镜左半肝切除加尾状叶切除术,以达到阴性切缘的完全切除。三维可视化技术使术前规划和术中指导更加精确,包括肿瘤位置的可视化、胆管和血管解剖步骤的模拟,以及肝切除范围的确定。术中进行血管骨骼化、淋巴结清扫和胆肠重建。
手术时间为 415 分钟,失血量为 100 毫升。术后病理组织学检查证实为中低分化胆管癌。切缘阴性(R0),淋巴结病理检查未见肿瘤(0/10)。患者术后第 10 天无并发症出院。
在高吞吐量肝脏手术中心,新辅助治疗后行腹腔镜根治性切除合并肝门部受累的 ICCA 是安全可行的。